Skip to main content

Rybelsus® (semaglutide) tablets

Rybelsus® (semaglutide) tablets is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Choose an area of interest below to access videos featuring specific information about Rybelsus®.


Glycemic Control Trials

Specific Population Studies

  • Cardiovascular Safety of Rybelsus® vs. Placebo (PIONEER 6 Study)

    This video discusses the trial-design and outcomes of the PIONEER 6 study. PIONEER 6 was a phase 3a, randomized, double-blind, multinational trial that enrolled 3183 adult patients (age ≥50 years) with type 2 diabetes. Eligible patients were at least 50 years of age with established cardiovascular (CV) disease or chronic kidney disease, or patients were at least 60 years of age with at least one CV risk factor.

The search will retrieve any scientific documents from the medical information database where the search terms match either the title or content of the document. The response(s) are not intended to offer recommendations for administering Novo Nordisk products in a manner inconsistent with approved labeling. To access the Prescribing Information for Novo Nordisk products, please click here.

Search for Letters

Find documents for this product by entering your search terms in the box below.

Text: double click to edit.

Have a Question?

Request information directly from the Novo Nordisk
Medical Information department.